PLAQUE PSORIASIS

This study is testing a new topical cream called MC2-01 for adults with plaque psoriasis. It compares the new cream against a standard gel treatment and a placebo cream to see which is better at clearing skin plaques and which is more convenient for patients to use. The main goal…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctors. Researchers will track how this treatment affects patients' quality of life and daily experiences over 2.5 years in real-world settings. The study obse…

This study is testing a new oral medication called CS32582 for adults with moderate-to-severe plaque psoriasis. About 220 participants will take either the capsule or a placebo for up to 12 weeks to see if it safely reduces skin plaques and improves quality of life. The main goal…

This study is testing whether an oral medication called deucravacitinib can safely and effectively treat moderate-to-severe plaque psoriasis in teenagers aged 12-17. Researchers will compare the drug against a placebo pill in 366 adolescent participants to see if it significantly…

This study aims to learn about the long-term safety and effectiveness of an investigational medication called ORKA-001 for adults with moderate-to-severe plaque psoriasis. It is open only to people who have already taken ORKA-001 in a previous company-sponsored study. Participant…

This study is testing if taking high-dose vitamin D pills daily makes a standard steroid cream work better for controlling plaque psoriasis. All participants will use the cream for 4 weeks, then half will add vitamin D while the other half gets a placebo pill for 12 weeks. The go…

This study is testing whether an investigational oral drug called ICP-332 can safely and effectively reduce the skin plaques and symptoms of moderate-to-severe psoriasis. About 172 adults with a significant history of psoriasis will be randomly assigned to receive either the real…

This study is testing a new drug called ORKA-001 to see if it can clear skin plaques in people with moderate-to-severe plaque psoriasis. About 160 adults will receive either the drug or a placebo to find the best dose and check how safe it is. The main goal is to see how many peo…

This study aims to compare the long-term safety of two psoriasis medications—deucravacitinib and ustekinumab—in people with moderate-to-severe plaque psoriasis who also have cardiovascular risk factors. Researchers will follow 3,040 participants for several years to track serious…

This study is testing a new oral medication called zasocitinib to see if it can effectively control skin symptoms and improve quality of life for children and teenagers with moderate-to-severe plaque psoriasis. It will involve about 110 participants aged 4 to under 18, comparing …

This study aims to see how well the medication deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. It will follow 150 patients who are newly starting this treatment to measure improvements in their skin condition and quality of l…

This study is testing an oral medication called deucravacitinib in children and teenagers aged 4 to 18 who have moderate to severe plaque psoriasis. The goal is to find the right dose for kids and see how well it clears their skin and how safe it is over time. The trial includes …

This study is testing a new oral medication called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 participants will take either the real pill or a placebo (sugar pill) for 12 weeks to see if it safely reduces skin redness, thickness, and scaling. …

This is the first study in people for a new pill called UA026, designed to treat plaque psoriasis by blocking a protein that causes inflammation. The main goal is to check the safety, side effects, and how the drug moves through the body in healthy volunteers and people with mode…

This study is testing whether the drug bimekizumab can help people with moderate-to-severe plaque psoriasis when other similar medications have not worked. It will involve 60 adults who previously tried and did not respond well to treatments targeting IL-17 or IL-23. Participants…

This study is testing whether an investigational drug called D-2570 can safely and effectively clear skin lesions in people with moderate to severe plaque psoriasis. About 390 participants will be randomly assigned to receive either D-2570 or a placebo (an inactive substance) for…

This study aims to see if adding two questions about morning stiffness and back pain, along with pictures, to an existing screening questionnaire helps doctors identify psoriatic arthritis in adults with moderate-to-severe plaque psoriasis. About 500 participants in Canada will f…